Metronomic chemotherapy dosing-schedules with estramustine and temozolomide act synergistically with anti-VEGFR-2 antibody to cause inhibition of human umbilical venous endothelial cell growth
- 1 January 2007
- journal article
- research article
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 46 (8), 1169-1177
- https://doi.org/10.1080/02841860701373603
Abstract
The effects of 'metronomic' or extended chemotherapy dosing schedules (ECS) are mediated through poorly understood anti-angiogenic mechanisms. ECS combined with biological anti-angiogenic agents have produced promising pre-clinical results.We have expanded the list of agents with an in vitro ECS profile to include the methylating agent temozolomide (Temodal) and the anti-mitotic agent estramustine (Estracyt). These agents were also combined with a specific anti-angiogenic inhibitor IMC-1C11 and a non-specific agent with anti-angiogenic properties, Compound 5h. The in vitro HUVEC ECS model system was optimised and cell proliferation assays undertaken.As a single agent, estramustine inhibited endothelial cell proliferation with an IC50 of 4.5 microM and was active at 10-33% of the maximum tolerated dose (MTD) from clinical schedules, whilst temozolomide had IC50 of 6.6 microM and was active at 1-6% of MTD. In combination, significant synergy was seen with IMC-1C11 in combination with either drug, whilst modest additive effects were observed with Compound 5h. None of the combinations resulted in significant cytotoxicity or apoptosis.The results show that ECS of temozolomide and estramustine can be significantly enhanced when combined with specific anti-angiogenic inhibitors in an in vitro HUVEC system.Keywords
This publication has 22 references indexed in Scilit:
- Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancerBMC Cancer, 2006
- High-Dose Celecoxib and Metronomic “Low-dose” Cyclophosphamide Is an Effective and Safe Therapy in Patients with Relapsed and Refractory Aggressive Histology Non–Hodgkin's LymphomaClinical Cancer Research, 2006
- Strategies for Delaying or TreatingIn vivoAcquired Resistance to Trastuzumab in Human Breast Cancer XenograftsClinical Cancer Research, 2006
- Metronomic Low-Dose Chemotherapy Boosts CD95-Dependent Antiangiogenic Effect of the Thrombospondin Peptide ABT-510: A Complementation Antiangiogenic StrategyClinical Cancer Research, 2005
- Hypoxia-inducible Factor 1α and Antiangiogenic Activity of Farnesyltransferase Inhibitor SCH66336 in Human Aerodigestive Tract CancerJNCI Journal of the National Cancer Institute, 2005
- The anti-angiogenic basis of metronomic chemotherapyNature Reviews Cancer, 2004
- Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478Proceedings of the National Academy of Sciences of the United States of America, 2003
- Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in miceJCI Insight, 2000
- Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicityJCI Insight, 2000
- Enzyme and metabolic inhibitorsPublished by Biodiversity Heritage Library ,1963